Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 220 | 24% |
| 2020 | 5 | 228 | 28% |
| 2021 | 9 | 320 | 33% |
| 2022 | 11 | 317 | 37% |
| 2023 | 10 | 357 | 40% |
| 2024 | 11 | 407 | 42% |
| 2025 from claims | – | 424 343–498 | 43% |
| 2026 forecast | – | 467 366–587 | 44% |
| 2027 forecast | – | 512 380–677 | 44% |
| 2028 forecast | – | 561 397–775 | 45% |
| 2029 forecast | – | 615 418–882 | 46% |
| 2030 forecast | – | 674 441–999 | 46% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in Virginia; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 40 | 1,299+18%/yr | +18%/yr | 0.6 | 0% | 2,280 in 2030+9.8%/yr |
| Texas | 28 | 1,099+13%/yr | +13%/yr | 0.5 | 0% | 2,130 in 2030+12%/yr |
| North Carolina | 13 | 383+6.3%/yr | +6.3%/yr | 0.4 | 0% | 640 in 2030+8.8%/yr |
| Tennessee | 9 | 328+6.6%/yr | +6.6%/yr | 0.5 | 0% | 490 in 2030+6.8%/yr |
| Maryland | 10 | 326+15%/yr | +15%/yr | 0.4 | 0% | 570 in 2030+9.9%/yr |
| Georgia | 8 | 323+8.8%/yr | +8.8%/yr | 0.4 | 0% | 940 in 2030+19%/yr |
| Kentucky | 9 | 226+16%/yr | +16%/yr | 0.5 | 0% | 310 in 2030+5.4%/yr |
| Alabama | 6 | 196+34%/yr | +34%/yr | 0.4 | 0% | 300 in 2030+7.4%/yr |
| South Carolina | 9 | 195−0.2%/yr | −0.2%/yr | 0.3 | 0% | 440 in 2030+15%/yr |
| Oklahoma | 2 | 164+3.5%/yr | +3.5%/yr | 0.3 | 0% | 450 in 2030+18%/yr |
| Louisiana | 7 | 162+8.9%/yr | +8.9%/yr | 0.4 | 0% | 220 in 2030+5%/yr |
| Mississippi | 4 | 119+13%/yr | +13%/yr | 0.3 | 0% | 110 in 2030−1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 21 | 418−0.3%/yr | −0.3%/yr | 0.40.9× | 0% | 480 in 2030+2.5%/yr |
| DBS & VNS | 5 | 275−0.4%/yr | −0.4%/yr | 0.30.8× | 0% | 420 in 2030+7.4%/yr |
| CSF shunts | 3 | 129−7.5%/yr | −7.5%/yr | 0.10.6× | 0% | 170 in 2030+4.6%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Virginia · Every state · Compare with Florida
Johnson & Johnson MedTech leads with 58% of company spending on these surgeons in 2025, −16 pts on 2024.
In 2025, 9 companies reported engagement with Virginia’s surgeons worth $125K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.